Objective To analyze the case distribution, trends and dispute causes in initial verification of occupational disease diagnosis (VODD) in Guangzhou City from 2015 to 2024. Methods A total of 1 006 cases applying for initial VODD in Guangzhou City from 2015 to 2024 were selected as the study subjects using the convenience sampling method. Data on their basic information, disease category distribution, acceptance status, and dispute-related characteristics were collected and analyzed. Results Among the 1 006 VODD application cases, 884 completed the verification process, accounting for 87.9%. Cases withdrawn by applicants, suspended appraisals, and non-accepted applications accounted for 8.7%, 2.3%, and 1.1%, respectively. Among the 884 cases that completed verification, the most prevalent occupational diseases were occupational noise-induced hearing loss, occupational tumors (benzene-induced leukemia), occupational pneumoconiosis, and occupational chronic benzene poisoning, accounting for 77.0%. Cases appraised as occupational diseases accounted for 41.5%, and the proportion showed a decreasing trend over the years (P<0.01). The inconsistency rate between VODD conclusions and occupational disease diagnostic conclusions was 4.4%, mainly attributable to insufficient cooperation during clinical examinations and incomplete submission of required materials. Conclusion The initial VODD in Guangzhou City from 2015 to 2024 demonstrated relatively concentrated disease categories and controllable dispute levels. Clinical examination compliance and standardization of material submission were key factors affecting consistency of appraisal conclusions. It is proposed that effective measures be adopted to rectify existing deficiencies, with the aim of further enhancing the standardization and refinement of VODD practice.

Objective:To investigate the clinical efficacy and adverse reactions of anlotinib combined with irinotecan in the third line treatment of metastatic esophageal cancer.Methods:From October 2018 to October 2019, 52 patients with metastatic esophageal cancer who had developed distant metastasis after receiving standard concurrent chemoradiotherapy and failed second-line chemotherapy were selected from Lu′an Hospital of Traditional Chinese Medicine of Anhui Province. The patients were divided into experimental group and control group by random number table method, with 26 cases in each group. The control group was given intravenous chemotherapy with irinotecan. The experimental group was treated with oral erlotinib combined with intravenous chemotherapy of irinotecan. The clinical efficacy and adverse reactions of the two groups were evaluated after 2 cycles of treatment.Results:Before treatment, there was no significant difference in Karnofsky performance status (KPS) score between the experimental group and the control group (76.15±7.52 vs. 74.62±8.59, t=-0.137, P=0.892). After treatment, there was no significant difference between the two groups (70.77±6.28 vs. 72.69±8.74, t=-1.761, P=0.084). However, after treatment, the KPS score in the experimental group was lower than that before treatment ( t=3.035, P=0.006). There was no statistical significance in the KPS scores of the control group before and after treatment ( t=1.000, P=0.327). Adverse reactions in the two groups were mainly grade 1-2. The incidences of grade 1-2 myelosuppression and diarrhea in the experimental group were 61.5% (16/26) and 46.2% (12/26), which were significantly higher than those in the control group (19.2%, 5/26 and 19.2%, 5/26), with statistically significant differences ( χ2=9.665, P=0.002; χ2=4.282, P=0.039). The disease control rate of the experimental group was 73.1% (19/26), which was significantly higher than that of the control group (46.2%, 12/26), and there was a statistically significant difference between the two groups ( χ2=3.914, P=0.048). The median progression-free survival of the experimental group and the control group was 52 days and 45 days, respectively, and there was a statistically significant difference ( χ2=4.692, P=0.032). Conclusion:Anlotinib combined with irinotecan in the third-line treatment of metastatic esophageal cancer has obvious efficacy, but to a certain extent, it increases the incidence of grade 1-2 myelosuppression and diarrhea, and the KPS score is lower compared with before treatment.